Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021

Authors: Hannah G. Rosenblum, Stephen C. Hadler, Danielle Moulia, Tom T. Shimabukuro, John R. Su, Naomi K. Tepper, Kevin C. Ess, Emily Jane Woo, Adamma Mba-Jonas, Meghna Alimchandani, Narayan Nair, Nicola P. Klein, Kayla E. Hanson, Lauri E. Markowitz, Melinda Wharton, Veronica V. McNally, José R. Romero, H. Keipp Talbot, Grace M. Lee, Matthew F. Daley, Sarah A. Mbaeyi, Sara E. Oliver

Published: 2021-08-10

DOI: 10.15585/mmwr.mm7032e4

Source: Full article

Abstract

No abstract found.

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson &amp; Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021

Abstract

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021